Patents by Inventor David Weiner

David Weiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250249094
    Abstract: The present invention provides compositions comprising two or more bispecific T cell engaging antibodies or nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.
    Type: Application
    Filed: April 7, 2023
    Publication date: August 7, 2025
    Inventor: David Weiner
  • Publication number: 20250236670
    Abstract: The present invention provides compositions comprising anti-Siglec antibodies and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.
    Type: Application
    Filed: March 31, 2023
    Publication date: July 24, 2025
    Inventors: David Weiner, Devivasha Bordoloi, Kar Muthumani, Mohamed Abdel-Mohsen
  • Patent number: 12357683
    Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing at least one Nipah virus (NiV) antigen that elicits an immune response in a mammal against NiV virus, and methods of use thereof.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: July 15, 2025
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Kar Muthumani, David Weiner
  • Publication number: 20250223369
    Abstract: The present invention provides natural killer engagers specific for activating natural killer cells through binding to Siglec-7, and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.
    Type: Application
    Filed: March 31, 2023
    Publication date: July 10, 2025
    Inventors: David Weiner, Devivasha Bordoloi, Kar Muthumani, Mohamed Abdel-Mohsen
  • Publication number: 20250215078
    Abstract: The present invention provides compositions comprising anti-Siglec antibodies and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.
    Type: Application
    Filed: March 31, 2023
    Publication date: July 3, 2025
    Inventors: David Weiner, Devivasha Bordoloi, Kar Muthumani, Mohamed Abdel-Mohsen
  • Publication number: 20250178995
    Abstract: A method of preparing glucaric acid comprising contacting D-glucose and oxygen with a first catalyst composition comprising a first copper radical oxidase, a single electron oxidizer, and a small molecule activator under conditions suitable for formation of glucodialdose; and contacting glucodialdose and oxygen with a second catalyst composition comprising a second copper radical oxidase, a single electron oxidizer and a small molecule activator under conditions suitable for the formation of a product mixture comprising glucaric acid or salts thereof. A method comprising contacting a sugar with a catalyst composition comprising an oxidoreductase, a single electron oxidizer and a small molecule activator under conditions suitable for the formation of one or more oxidized sugar oxidation products comprising glucaric acid wherein the oxidoreductase comprises at least two copper radical oxidases, at least two mutated copper radical oxidases or combinations thereof.
    Type: Application
    Filed: December 2, 2024
    Publication date: June 5, 2025
    Applicant: Solugen, Inc.
    Inventors: Toni M. Lee, David Weiner, Konrad V. Miller, Gaurab Chakrabarti, Sean Hunt
  • Patent number: 12296001
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Crimean-Congo hemorrhagic fever virus (CCHFV) antigens. Immunomodulatory methods and methods of inducing an immune response against CCHFV are disclosed. CCHFV glycoprotein immunogens are disclosed.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: May 13, 2025
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Kar Muthumani, David Weiner
  • Publication number: 20250134988
    Abstract: The present invention generally relates to immunogenic compositions comprising pan-coronavirus antigenic polypeptides and antibodies, and methods of use thereof for the treatment and prevention of coronavirus infection.
    Type: Application
    Filed: February 3, 2023
    Publication date: May 1, 2025
    Inventors: Daniel Kulp, Susanne Walker, Kevin Liaw, Ziyang Xu, David Weiner
  • Publication number: 20250127884
    Abstract: The present invention generally relates to immunogenic compositions (e.g., vaccines and immunotherapies) that induce an immune response against Epstein Barr Virus (EBV)-associated antigens. The present invention also relates to methods of use thereof for the treatment and prevention of EBV infection, EBV-associated cancer, or a combination thereof. In various embodiments, the EBV antigen comprises BamHI-A rightward frame 1 (BARF1).
    Type: Application
    Filed: August 30, 2022
    Publication date: April 24, 2025
    Inventors: David Weiner, Xizhou Zhu
  • Publication number: 20250121054
    Abstract: Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen. SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.
    Type: Application
    Filed: December 20, 2024
    Publication date: April 17, 2025
    Inventors: Jian Yan, Kate Broderick, David Weiner, Kar Muthumani, Ami Patel
  • Patent number: 12268735
    Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.
    Type: Grant
    Filed: March 7, 2023
    Date of Patent: April 8, 2025
    Assignees: The Wistar Institute of Anatomy and Biology, The Trustees of the University of Pennsylvania
    Inventors: David Weiner, Ami Patel, Sarah Elliott
  • Publication number: 20250101399
    Abstract: Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.
    Type: Application
    Filed: May 10, 2024
    Publication date: March 27, 2025
    Inventors: David Weiner, Jian Yan, Bernadette Ferraro, Niranjan Y. Sardesai, Mathura P. Ramanathan
  • Patent number: 12195536
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets CTLA-4. The disclosure also provides a method of preventing and/or treating disease, such as cancer, in a subject using the composition of the invention.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: January 14, 2025
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: David Weiner, Elizabeth Duperret
  • Patent number: 12194000
    Abstract: Provided herein is an immunogenic composition comprising a synthetic consensus antigen to chondroitin sulfate proteoglycan 4 (CSPG4) protein which is abundant in many cancers. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: January 14, 2025
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventor: David Weiner
  • Publication number: 20250011265
    Abstract: A chemoenzymatic method of producing a polyhydroxybenzene includes contacting glucose with one or more biocatalysts under conditions suitable for the formation of D-glucodialdose; and thermally treating D-glucodialdose in the presence of a dehydration catalyst under conditions suitable for the formation of the polyhydroxybenzene. A chemoenzymatic method of producing 1,2,3,4-tetrahydroxybenzene includes contacting glucose with a mutated copper radical oxidase and catalase under conditions suitable for the formation of D-glucodialdose; and subjecting D-glucodialdose and a dehydration catalyst to temperatures ranging from about 40° C. to about 100° C. suitable for the formation of 1,2,3,4-tetrahydroxybenzene.
    Type: Application
    Filed: February 22, 2023
    Publication date: January 9, 2025
    Applicant: SOLUGEN, INC.
    Inventors: Shuai Qian, Toni M. Lee, Camille Boucher-Jacobs, Brian Fisher, Gaurab Chakrabarti, Sean Hunt, David Weiner
  • Publication number: 20250011401
    Abstract: Disclosed herein are compositions comprising structurally modified DNA encoded antibodies (DMAbs), methods of structurally modifying DMAbs, and methods of using structurally modified DMAbs.
    Type: Application
    Filed: July 8, 2024
    Publication date: January 9, 2025
    Inventors: David Weiner, Ghiabe Guibinga, Neil Cooch, Charles Reed
  • Publication number: 20240417448
    Abstract: Disclosed herein are compositions comprising a recombinant nucleic acid sequence encoding a bispecific anti-HIV natural killer engager, a fragment thereof, a variant thereof, or a combination thereof, and methods of use thereof.
    Type: Application
    Filed: October 28, 2022
    Publication date: December 19, 2024
    Inventors: David Weiner, Mansi Purwar, Abhijeet Kulkarni, Daniel Park, Devivasha Bordoloi, Pratik Bhojnagarwala
  • Publication number: 20240409649
    Abstract: The present invention provides natural killer engagers specific for activating natural killer cells through binding to a Siglec, and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.
    Type: Application
    Filed: October 6, 2022
    Publication date: December 12, 2024
    Inventors: David Weiner, Devivasha Bordoloi
  • Publication number: 20240409619
    Abstract: Disclosed herein are antibodies to SARS-COV-2 antigens and recombinant nucleic acid sequences that encode the SARS-COV-2 antibodies. The disclosure also provides a method of preventing and/or treating a SARS-COV-2 infection or disease or disorder associated with SARS-COV-2 infection (e.g., COVID-19) in a subject using said compositions and methods.
    Type: Application
    Filed: October 13, 2022
    Publication date: December 12, 2024
    Inventors: David Weiner, Elizabeth Parzych, Trevor Smith, Ami Patel, Daniel Kulp
  • Publication number: 20240409618
    Abstract: Disclosed herein are nucleic acid encoded Fc-modified antibodies and methods of use of the same for the treatment of diseases and disorders.
    Type: Application
    Filed: October 13, 2022
    Publication date: December 12, 2024
    Inventors: David Weiner, Elizabeth Parzych, Trevor Smith, Ami Patel, Daniel Kulp